Generic Name and Formulations:
Iohexol 9.7g (equivalent to 4.5g carbon bound iodine); per bottle; pwd for oral soln after reconstitution.
Otsuka America Pharmaceutical, Inc.
Indications for ORALTAG:
For opacification of the gastrointestinal (GI) tract during computed tomography (CT) of the abdomen and pelvis.
Limitations Of use:
Not for diagnostic examination of the GI tract.
Adults and Children:
Administer 20–60mins before imaging. <3yrs: up to 4.5g iodine (1 bottle); max 4.5g total iodine dose. 3–18yrs: up to 9g iodine (<1–2 bottles); max 9g total iodine dose. >18yrs: 4.5–9g iodine (1–2 bottles); max 9g total iodine dose. For higher concentration preparation at lower volumes: see full labeling.
Do not administer Oraltag parenterally; risk of severe reactions (eg, sepsis). Previous reaction to an iodinated contrast agent. Allergic disorders. Have emergency resuscitation equipment and trained personnel available. Elderly. Pregnancy. Nursing mothers: consider pumping and discarding breast milk for 10hrs post-administration.
Radiographic contrast medium.
May alter results of thyroid function tests; if indicated, perform prior to administration.
Nausea, vomiting, diarrhea; hypersensitivity reactions.
Single-use bottle (20oz)—12, 25
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline